---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008484"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:31:45.119325+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcus Q1 net loss $68M; ARC-7 domvanalimab arms continue to differentiate

## Summary
- Cash $1.34B, up from $681M due to $725M from Gilead in Jan 2022; funding into 2026.
- Q1 revenue $18M (up from $9.5M YoY); net loss improved to $68M from $72.6M YoY.
- Third IA of ARC-7: domvanalimab arms showed meaningful differentiation in ORR and DoR vs anti-PD1 alone; no unexpected safety.
- Phase 3 STAR-121 (domvanalimab+zim+chemo vs pembro+chemo) for 1L NSCLC PD-L1 all-comers planned Q4 2022.
- R&D expenses $61.2M (down from $66.4M) due to cost-sharing with Gilead; G&A increased to $24M.

## SEC filing metadata
- accession: 0000950170-22-008484
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017022008484/0000950170-22-008484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017022008484/rcus-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008484
- JSON: https://secwatch.observer/filing/0000950170-22-008484.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.